Interview with Sudhir Agrawal

As the life sciences industry continues to push the boundaries of innovation, few areas have evolved as dramatically as RNA therapeutics. Once viewed with skepticism, antisense technology has matured into a powerful and versatile platform—one that is now reshaping how genetic diseases are understood and treated.

In a recent conversation with Oxford Global’s Cerlin Roberts, Sudhir Agrawal, Founder and President of ARNAY Sciences LLC and a pioneer in the field, reflected on a journey spanning more than four decades. His perspective offers a compelling view of how persistence, chemistry, and biology have converged to unlock a new era of medicine.

From Skepticism to Clinical Reality

When antisense therapeutics first emerged in the late 1970s, the concept was ambitious: use synthetic nucleic acids to target and modulate gene expression. At the time, the idea faced considerable doubt.

Yet progress came steadily—through both failure and success. “It wasn’t a single breakthrough,” Agrawal noted, but rather a series of incremental advances that built confidence in the approach.

The past decade, however, has marked a turning point. Multiple approved drugs have validated antisense as a therapeutic modality, demonstrating not only its feasibility but its broad applicability. What was once theoretical is now delivering tangible benefits to patients.

Chemistry: The Foundation of Progress

Early challenges in antisense development were rooted in stability. RNA and DNA molecules are inherently fragile, rapidly degraded in the body. Overcoming this required significant advances in oligo chemistry—transforming these molecules into viable drugs.

Innovations introduced in the 1990s, including modifications that enhance stability and safety, remain foundational today. These chemical advances enabled antisense compounds to survive long enough to reach their targets and exert therapeutic effects.

But chemistry alone was not enough.

Cracking the Delivery Challenge

One of the most significant breakthroughs in recent years has been the ability to deliver antisense compounds effectively within the body—particularly to the liver.

Understanding delivery mechanisms has opened up a wide range of therapeutic targets, allowing researchers to modulate gene expression with increasing precision. What was once a major barrier is now a key enabler of progress.

As Agarwal highlights, the last five years have been especially important in refining these delivery strategies, bringing antisense therapies closer to routine clinical application.

A New Model for Drug Development

RNA medicines are fundamentally changing how therapies are developed. Rather than relying on lengthy discovery processes, researchers can now start with genetic information itself.

Once a disease-causing mutation is identified, a corresponding antisense compound can be designed to target it directly. This streamlined approach enables rapid progression from concept to clinic.

In some cases, treatments are now being developed for individual patients—so-called “n-of-1” therapies—highlighting the growing potential of precision medicine.

Beyond Chemistry: Rethinking RNA Structure

While chemical modification has driven much of the field’s success, new innovations are emerging that go beyond chemistry alone.

One of the most promising areas is the exploration of RNA structure. By altering the shape of RNA molecules—from linear to circular forms—researchers are observing significant improvements in potency and specificity.

These circular RNA structures, still in early stages of development, could represent the next leap forward in RNA therapeutics, offering new ways to enhance performance and expand therapeutic reach.

A Complementary Ecosystem of RNA Technologies

Antisense therapeutics do not exist in isolation. Instead, they form part of a broader ecosystem that includes siRNA, mRNA, and RNA editing technologies.

While each approach operates differently, they share a common foundation: the use of synthetic nucleic acids to interact with biological targets through precise base pairing.

Rather than competing, these technologies are increasingly seen as complementary—together expanding the toolkit available to researchers and clinicians.

Speed, Scale, and the Future of Treatment

Perhaps the most transformative aspect of RNA therapeutics is speed. Traditional drug development—whether small molecules or biologics—can take years or even decades.

In contrast, RNA-targeted therapies can be designed rapidly once a genetic sequence is known. In some cases, treatments can be developed within a year, dramatically accelerating the path to patient care.

For many genetic diseases that were previously untreatable, this represents a profound shift. The combination of speed, efficiency, and high probability of success is redefining expectations across the industry.

Looking Ahead

As RNA science continues to advance, the future of medicine is becoming increasingly programmable—driven by sequence, guided by biology, and enabled by innovation.

Agrawal’s insights reflect a field that has moved from uncertainty to confidence, from concept to clinic. The next chapter will likely be defined not just by new discoveries, but by the ability to deliver them—faster, more precisely, and at scale.

In the end, the promise of antisense therapeutics is not just scientific—it is deeply human: the ability to treat diseases once thought beyond reach.